The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Dark Blue Therapeutics; Diffusion Pharmaceuticals; EMD Serono; F-Star; Genmab; Gerson and Lehrman Group; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; Idience; Ignyta; ImmuneSensor Therapeutics; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Natera; Nexys Therapeutics; Novocure; OncoSec; Ono Pharmaceutical; Oregon Health & Science University (OHSU); Pegascy; PER; Pfizer; Piper Sandler; ProLynx; Repare Therapeutics; resTORbio; Roche; Schrodinger; Terremoto Biosciences; Theragnostics; Varian Medical Systems; Versant Health; Vibliome Therapeutics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); ImmuneSensor Therapeutics (Inst); Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)
 
Abdelaziz M. Elhaddad
No Relationships to Disclose
 
Rachel N. Grisham
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Corcept Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Intellisphere; Myriad Genetics; Signatera; SpringWorks Therapeutics; Verastem
Research Funding - Bayer (Inst); Context Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); SpringWorks Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - EMD Serono
Other Relationship - Aptitude Health; Cardinal Health; MCM Education; OncLive; Prime Oncology
(OPTIONAL) Uncompensated Relationships - Verastem
 
John Turner Hamm
Consulting or Advisory Role - Meda Pharmaceuticals
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst)
 
Douglas Kanter Marks
Honoraria - Seagen
Consulting or Advisory Role - AstraZeneca; Lilly; Seagen
Speakers' Bureau - MJH Healthcare Holdings, LLC
Research Funding - Agendia; Merck (Inst)
Travel, Accommodations, Expenses - Agendia
 
Geoffrey Shapiro
Consulting or Advisory Role - Artios; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Fusion Pharmaceuticals; ImmunoMet; Janssen Oncology; Kymera; Lilly; Merck Serono; Pfizer; Syros Pharmaceuticals; Xinthera; Zentalis
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Biosplice (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb/Medarex (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Cyclacel (Inst); Cyteir (Inst); Esperas Pharma (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
 
Christophe Le Corre
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jerry Li
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Tun Tun Lin
Employment - Pfizer; Sanofi
Stock and Other Ownership Interests - Pfizer; Sanofi
 
Feng Liu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Lara Malky
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Allison R Moreau
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Heather Neumann
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; EMD Serono; Genentech; Ipsen; MapKure; Novartis; PIC Therapeutics; Relay Therapeutics; Syros Pharmaceuticals; Vibliome Therapeutics
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Biogen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Moderna Therapeutics; Pfizer; Regeneron; Vertex; West Pharmaceutical
Consulting or Advisory Role - Pliant
Research Funding - Abbvie (Inst); Agenus (Inst); Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Johnson & Johnson/Janssen (Inst); Jounce Therapeutics (Inst); Kinnate Biopharma (Inst); KLUS Pharma (Inst); KSQ Therapeutics (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); NGM Biopharmaceuticals (Inst); Odonate Therapeutics (Inst); Onconova Therapeutics (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Theratechnologies (Inst); Tizona Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst)